Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer
Jaime Ceballos-Viro (1), José M López-Picazo (1), José L Pérez-Gracia (1), Jesús J Sola (2), Gregorio Aisa (2), Ignacio Gil-Bazo (1)
(1) Department of Oncology, Clínica Universidad de Navarra, Pio XII 36, 31008 Pamplona, Spain
(2) Department of Pathology, Clínica Universidad de Navarra, Pio XII 36, 31008 Pamplona, Spain
Fibrosing cholestatic hepatitis (FCH) is a variant of viral hepatitis reported in hepatitis B virus or hepatitis C virus infected liver, renal or bone transplantation recipients and in leukemia and lymphoma patients after conventional cytotoxic chemotherapy.
FCH constitutes a well-described form of fulminant hepatitis having extensive fibrosis and severe cholestasis as its most characteristic pathological findings. Here, we report a case of a 49-year-old patient diagnosed with small-cell lung cancer who developed this condition following conventional chemotherapy-induced immunosuppression.
This is the first reported case in the literature of FCH after conventional chemotherapy for a solid tumor. In addition to a detailed report of the case, a physiopathological examination of this potentially life-threatening condition and its treatment options are discussed.
CITA DEL ARTÍCULO World J Gastroenterol. 2009 May 14;15(18):2290-2